Riverside Partners raised $561 million with its fifth fund. Riverside Fund V invests in middle market healthcare and technology companies. Atlantic-Pacific Capital served as Riverside’s placement agent. Choate, Hall & Stewart was counsel.
Riverside Partners, a leading private equity firm focused on investing in middle market healthcare and technology companies, today announced the closing of Riverside Fund V with $561 million of committed capital.
Riverside Fund V follows the firm’s $406 million Riverside Fund IV, which was raised in 2009. Riverside Partners was able to secure very significant support from its existing investors. Fund V builds on the firm’s 23-year track record of partnering with founder- and management-owned healthcare and technology companies.
“We are very pleased to have completed our fundraising, achieving our hard cap in six months. We are particularly appreciative of the substantial support from our existing investors, as well as several new investors, during a crowded fundraising environment,” said David Belluck, General Partner at Riverside Partners, LLC. “We are excited about the new fund’s prospects. Our team continues to actively invest in healthcare and technology businesses that are consistent with the businesses we have worked with over our 23-year history.”
Atlantic-Pacific Capital Inc. served as Riverside’s placement agent for Riverside Fund V. Choate, Hall & Stewart, LLP served as counsel to the fund.
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firm focusing on growth-oriented companies in the healthcare and technology industries. Riverside is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. The partners at Riverside have managed more than $700 million in investments in over 55 companies. The firm is currently focused on companies with revenues between $20 -$200 million and with $5 – $25 million of EBITDA.